MariTide (maridebart cafraglutide) is a bispecific glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — the same drug class as Eli Lilly’s approved weight loss drug, Zepbound (tirzepatide). Amgen is investigating MariTide as a potential therapy for obesity and Type 2 diabetes.
The trial enrolled 465 adults who are obese or overweight and 127 adults with Type 2 diabetes. Study participants received a monthly placebo or doses of 140 milligrams, 280 milligrams or 420 milligrams of MariTide. The dose escalation to 420 milligrams occurred either over four weeks or 12 weeks.
For non-diabetic participants who are obese or overweight, the average weight loss was about 20%. Those with diabetes who are either obese or overweight averaged 17% weight loss and lowered their average hemoglobin A1C by up to 2.2 percentage points.
Amgen researchers did not observe a weight loss plateau.
The most common side effects were gastrointestinal events, including nausea, vomiting and constipation. Participants who experienced a weight loss of at least 15% are eligible for part two of the phase 2 study, which is investigating the drug beyond 52 weeks.
Based on the trial’s results, Amgen will launch a phase 3 study to research MariTide’s effects on obesity and obesity-related conditions. The drugmaker is also advancing an obesity pipeline with oral and injectable candidates.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
